Home/Pipeline/Complement-targeting nanobodies

Complement-targeting nanobodies

Complement-mediated diseases

Discovery/PreclinicalActive; Part of complement inhibitor platform.

Key Facts

Indication

Complement-mediated diseases

Phase

Discovery/Preclinical

Status

Active; Part of complement inhibitor platform.

Company

Q32 Bio

About Q32 Bio

Q32 Bio is focused on discovering and developing innovative therapies that restore immune homeostasis in severe autoimmune and inflammatory diseases. The company's most advanced program, bempikibart, has shown promising clinical activity and a favorable safety profile in a Phase 2a trial for alopecia areata. Led by an experienced team of industry veterans, Q32 Bio is advancing a pipeline centered on modulating both the adaptive (via IL-7/TSLP) and innate (via complement) immune systems, with strategic evaluation ongoing for its complement platform.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases Alopecia Areata

Other Complement-mediated diseases Drugs

Drug	Company	Phase	Status
Pozelimab	Regeneron Pharmaceuticals	Phase 2/3	Active
ARGX-117	Argenx	Phase 1/2	Active
ANX009	Annexon	Preclinical	IND-enabling
ADX-096	Q32 Bio	Discovery/Preclinical	Active; Strategic options being evaluated.
C3d mAb fusions	Q32 Bio	Discovery/Preclinical	Active; Part of complement inhibitor platform.
RLYB116	Rallybio	Phase 1	Confirmatory PK/PD study ongoing